20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Joint power instead of duplicate structures:Berlin’s research community is further advancing its research excellence by establishing a high-performance, cross-institutional infrastructure for data and AI. With a joint agreement signed on 18 September 2026, the Berlin University Alliance (BUA), the Helmholtz-Zentrum Berlin (HZB) and the Zuse Institute Berlin (ZIB) are paving the way for a joint data science and AI centre in Berlin-Dahlem and Adlershof.
- New technique could make MRI more preciseA team of researchers at the University of Stuttgart and HZB has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.
- BESSY II: High-resolution insights into individual biomolecules and catalystsVery small biological samples and even individual biomolecules can now be examined under near-physiological conditions with high confidence at the BESSY II infrared beamline with a newly validated and improved technique: The nanoscale infrared spectroscopy (s-SNOM) with ultra-thin silicon-based membranes. An international team demonstrated after an initial proof of concept, that high-resolution (a few tens of nanometres) nano-IR measurements reliably match expected far-field IR spectra in an aqueous environment. This methodological advance provides a solid foundation for studying biomaterials or observing catalytic processes in a liquid environment.